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INTRODUCTION
Endoscopic mucosal resection (EMR) has been established
as a therapeutic alternative for early gastric cancer (EGC) con-
fined to the mucosa and its premalignant lesions (1). For EGC,
EMR provides a survival rate of more than 90% relative to
that of surgery if the technique is applied with the appropri-
ate indication (2). Moreover, morbidity and mortality asso-
ciated with surgery can be avoided, and specimens can be
obtained for accurate staging (3). The frequency of EMR has
increased worldwide and the emergence of a newer technique,
endoscopic submucosal dissection (ESD), extended the indi-
cation criteria of EMR (4). However, this procedure inevitably
results in formation of large ulcers at the resected area, which
occasionally bleed. 
The characteristics and healing mechanism of EMR-in-
duced ulceration are not fully understood. Furthermore, the
duration of treatment and optimal treatment options are con-
troversial. At present, it is evident that an abundant blood
supply at the margin of EMR-induced ulcer is an important
factor in promoting ulcer healing. Healing of gastric ulcers
requires angiogenesis in the granulation tissue at the base of
the ulcer, together with replication of epithelial cells at the
ulcer margins and subsequent reestablishment of glandular
architecture (5). Epithelial and endothelial cell proliferation
is largely driven by various growth factors. In the case of angio-
genesis, vascular endothelial growth factor appears to be among
the most important (6). In addition, fibroblast growth factor-
2 and platelet derived growth factor are known to play an
important role in gastric ulcer healing (7, 8).
Rebamipide is a mucosal protective and ulcer healing drug
that stimulates prostaglandin generation in gastric mucosa,
and improves not only speed but also quality of ulcer heal-
ing (9). Supporting this, experimental studies have indicat-
ed that rebamipide treatment directly stimulated angiogen-
esis and activated pro-angiogenic growth factors (10). Theo-
retically, rebamipide can be a potential therapeutic agent in
EMR-induced gastric ulcers, however there have been no stud-
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Rebamipide May Be Comparable to H2 Receptor Antagonist in Healing
Iatrogenic Gastric Ulcers Created by Endoscopic Mucosal Resection:
A Prospective Randomized Pilot Study
Endoscopic mucosal resection (EMR) results in the formation of iatrogenic gastric
ulcers and the optimal treatments for such ulcers are still unclear. We aimed to eval-
uate the efficacy of rebamipide in the management of EMR-induced ulcers by com-
paring it with an H2 receptor antagonist. After EMR, patients were randomly assigned
into either rebamipide or famotidine groups. All patients received a one-week lan-
soprazole 30 mg q.d. therapy followed by three-week famotidine (20 mg b.i.d.) or
rebamipide (100 mg t.i.d.) therapy. Four weeks after the treatments, ulcer sizes,
stages, bleeding rates, and ulcer-related symptoms were compared using endos-
copy and a questionnaire. A total of 63 patients were enrolled in this study. Finally,
51 patients were analyzed, 26 in rebamipide and 25 in famotidine group. Baseline
characteristics were not significantly different between the two groups. Four weeks
after EMR, the two groups were comparable in terms of ulcer reduction ratio (P=
0.297), and ulcer stage (P=1.000). Moreover, no difference was observed with regard
to ulcer-related symptoms, drug compliance, adverse drug event rates, and bleed-
ing rates. Our data suggest that rebamipide is not inferior to famotidine in healing
iatrogenic gastric ulcers, and could be a therapeutic option in the treatment of such
ulcers.
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ies concerning its efficacy in EMR-induced ulcers. Accord-
ingly, we aimed to evaluate the efficacy of rebamipide on
EMR-induced ulcers by comparing it to famotidine, an H2
receptor antagonist (H2RA) through a prospective random-
ized study. 
MATERIALS AND METHODS
Patients 
The patients who underwent EMR including ESD for gas-
tric adenoma or early gastric cancer confined to the mucosa
were consecutively enrolled in this study between Decem-
ber 2006 and April 2008 at the Severance Hospital in Korea.
Patients 18 yr of age or older were eligible to participate in
this study. Exclusion criteria included patients taking H2RA,
proton pump inhibitors (PPI), nonsteroidal anti-inflamma-
tory drugs (NSAIDs), anticoagulants, or glucocorticoids of
which potency is equivalent to prednisolone ≥10 mg with-
in the past seven days. Furthermore, patients who should con-
tinue use of ulcer-inducing medications during the study,
such as aspirin, NSAIDs, glucocorticoids, or anticoagulants,
who had past surgical history of the stomach or esophagus,
and women who were lactating, pregnant, or intended to
become pregnant during the study period, were also exclud-
ed. At enrollment, baseline characteristics such as sex, age,
and comorbid diseases were recorded. The institutional review
board of the Severance Hospital approved the study protocol
and all patients provided written informed consent to par-
ticipate in this study (4-2006-0005).
Endoscopic mucosal resection
EMR was done by one of the following methods: 1) ESD
using an insulation-tipped electrosurgical knife, 2) precutting
and resection using a snare (EMR-P), 3) EMR using a trans-
parent cap (EMR-C), or 4) snare polypectomy. Before EMR,
the maximal diameter and lesion location were recorded. After
EMR, ulcer dimensions were recorded. Ulcer dimensions were
calculated by multiplying the maximal diameter by the per-
pendicular diameter. Diameter was measured with biopsy
forceps (Olympus, Tokyo, Japan) placed on the ulcer surface,
using the width between fully-opened forceps (7 mm) (7).
Rapid urease test (CLOtest�; Kimberley-Clark, Draper, UT,
USA) was performed with specimens obtained from the lesser
curvature of the antrum for evaluation of Helicobacter pylori
infection status. Hemoglobin and coagulation profile (pro-
thrombin time and activated partial thromboplastin time)
were also checked one day before EMR.
Study protocol
Patients were randomly assigned into either the rebamipi-
de or famotidine group after EMR (Fig. 1). All EMR proce-
dures were performed by one specialized endoscopist. All pati-
ents received pantoprazole 40 mg intravenous, b.i.d. on the
day EMR was performed. Starting the next day, lansoprazole
(30 mg) was administered once daily to patients in both groups
for seven days. Two days after the EMR, patients were dis-
charged if no bleeding or perforation occurred. After complet-
ing one week of lansoprazole treatment, patients received a
three week treatment of rebamipide 100 mg t.i.d. or famo-
tidine 20 mg b.i.d. During the study period, patients were
instructed not to take any other medications that may affect
ulcer healing. 
Primary objectives included the evaluation of gastric ulcer
healing and clinical symptoms. Gastric ulcer healing was
assessed by endoscopic examination 4 weeks after EMR. Ulcer
healing was assessed by measuring changes in both ulcer stage
and size. Gastric ulcer stage was classified by using a six-stage
system as proposed by Sakita and Fukutomi: active (A1, A2),
healing (H1, H2), and scarring (S1, S2) (11). Ulcer dimen-
sions were measured with biopsy forceps, by the same method
as that used at the time of EMR. Endoscopists were not in-
formed about the drugs the patients had received at the time
of EMR or endoscopy. 
Clinical symptoms, drug adverse events, complications,
and drug compliance were assessed by a physician via an inter-
view and questionnaire at an outpatient clinic. Epigastric pain
was recorded using a four-grade system (12).
Statistical analyses
Baseline characteristics of patients were compared by either
the Fisher’s exact test or t-test. Ulcer reduction ratios were
calculated by dividing the ulcer dimension at four weeks after
EMR by the initial ulcer dimension (13). Ulcer reduction
ratios were compared by the Mann-Whitney test. The stage
of ulcer, symptoms during treatment, and frequency of adverse
events were compared by the Fisher’s exact test. P values of
less than 0.05 were considered to be statistically significant.
Statistical analysis was performed using SPSS for Windows
(version 12.0; SPSS Inc., Chicago, IL, USA). 
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Fig. 1. Flow diagram of
the study.
EMR, endoscopic mu-
cosal resection; PPI, pro-
ton pump inhibitor; iv,
intravenous.
D-0
EMR iv PPI
D+1
Lansoprazole for 7 days
D+28
Follow-up 
endoscopy
D+8
Rebamipide or famotidine
for 21 days
RESULTS
A total of 63 patients were enrolled in this study and were
randomly assigned to each group at a ratio of 32:31. Twelve
patients in the two groups (6 in rebamipide group and 6 in
famotidine group) were excluded from the final analyses be-
cause four underwent additional gastrectomy or endoscopic
treatments after confirmation of cancer involvement in the
resection margin, six had violated study protocol or taken inad-
equate medications, and two were lost during follow-up (Fig.
2). In baseline characteristics such as sex, age, comorbidity,
blood test, and rapid urease test positivity, there were no sig-
nificant differences between the two groups (Table 1). More-
over, there were no significant differences between the two
groups with regard to the characteristics of gastric ulcers cre-
ated by EMR such as size, location, EMR method for lesion,
hemoclipping after EMR, and histopathology (Table 2).
The stages of the 51 ulcers at follow-up endoscopy were com-
pared between the two groups. There was no significant differ-
ence in the distribution of ulcer stages between the two groups
(P=1.000). Furthermore, ulcer reduction ratios were found
to be similar between the two groups (P=0.297) (Table 3). 
To specifically evaluate the effect of rebamipide in large
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Fig. 2. Flow diagram of patient enrollment, assignment, and com-
pletion of the study.
APC, argon plasma coagulation.
Rebamipide
group (n=32)
Famotidine 
group (n=31)
Completion of
study protocol
(n=26)
Completion of
study protocol
(n=25)
Study enrollment
(n=63)
1 underwent surgery
1 underwent APC
2 violated study
protocol
2 underwent
surgery
4 violated
study protocol
2 follow-up loss
INR, international normalized ratio; CLO, campylobacter-like organism.
Variables
Rebamipide
group (n=26)
Famotidine
group (n=25)
P
value
Age (mean±S.D., yr) 62.2±12.1 61.8±9.2 0.897
(34-82) (46-78)
Male 19 (73.1%) 15 (60.0%) 0.382
Comorbidity
Hypertension 10 (38.5%) 9 (36.0%) 1.000
Diabetes mellitus 4 (15.4%) 2 (8.0%) 0.668
Smoking 2 (7.7%) 4 (16.0%) 0.667
Hemoglobin (g/dL) 12.8±1.5 13.2±1.4 0.321
(mean±S.D.)
Prothrombin time (INR) 1.0±0.1 1.0±0.1 0.493
(mean±S.D.)
Activated partial thrombo- 31.4±2.4 31.1±2.7 0.686
plastin time (sec) 
(mean±S.D.)
Positive CLO test 6 (23.1%) 4 (16.0%) 0.137
Table 1. Demographic and clinical characteristics of patients in
both groups
EMR, endoscopic mucosal resection; EMR-C, EMR using a transpar-
ent cap; EMR-P, EMR by precutting and resecting using a snare; ESD,
endoscopic submucosal dissection; WD, well differentiated; MD, mod-
erately differentiated.
Rebamipide
group (n=26)
Characteristics
Famotidine
group (n=25)
P
value
Location 0.613
Antrum or angle 21 (80.9%) 19 (76.0%)
Lower body 3 (11.5%) 3 (12.0%)
Mid-body 1 (3.8%) 2 (8.0%)
Upper body 1 (3.8%) 1 (4.0%)
Method of EMR 0.499
Snare polypectomy - 2 (8.0%)
EMR-C - 1 (4.0%)
EMR-P 4 (15.4%) 3 (12.0%)
ESD 22 (84.6%) 19 (76.0%)
En bloc resection 21 (80.8%) 20 (80.0%) 1.000
Hemoclipping 13 (50.0%) 10 (40.0%) 0.377
Histology 0.404
Adenoma, low grade 7 (27.0%) 11 (44.0%)
Adenoma, high grade 3 (11.5%) 2 (8.0%)
Adenocarcinoma, WD 5 (19.2%) 10 (40.0%)
Adenocarcinoma, MD 7 (26.9%) -
Others 4 (15.4%) 2 (8.0%)
Table 2. Characteristics of gastric ulcers created by EMR 
*Ulcer reduction ratio is defined as ulcer dimension at four weeks after
EMR/initial ulcer dimension created by EMR×100. 
EMR, endoscopic mucosal resection.
Variables
Rebamipide
group (n=26)
Famotidine
group (n=25)
P
value
Ulcer dimension at four 86.7±92.6 57.9±89.9 0.265
weeks after EMR (mm2) (0-325) (0-360)
(mean±S.D.)
Initial ulcer dimension created 813.8±528.8 682.4±628.9 0.424
by EMR (mm2) (170-2,112) (109-2,752)
(mean±S.D.)
Ulcer reduction ratio* 12.8±15.3 8.4±13.9 0.297
(mean±S.D.) (0-58.8) (0-71.4)
Ulcer stage, four weeks after EMR 1.000
A2 3 (11.5%) 2 (8.0%)
H1 12 (46.2%) 5 (20.0%)
H2 8 (30.8%) 16 (64.0%)
S1 3 (11.5%) 2 (8.0%)
Table 3. Comparison of ulcer size, ulcer stage, and ulcer reduc-
tion ratio
iatrogenic ulcers, we performed subgroup analysis for patients
who underwent ESD. Twenty-two out of 26 (84.6%) in reba-
mipide group and 19 out of in 25 (76.0%) in famotidine group
underwent ESD. Baseline characteristics were comparable
between the two groups (data not shown). Ulcer reduction
ratios were not significantly different between the two groups
(9.98 vs. 9.93, P=0.991). Furthermore, the distribution of
ulcer stages was not significantly different (P=0.746) (three
in A2, 10 in H1, 6 in H2, and 3 in S1 stage; rebamipide group
vs. 2 in A2, 5 in H1, 11 in H2, and 1 in S1 stage; famotidine
group).
The distribution of epigastric pain during the period of
anti-ulcer medication was not different between the two
groups (Table 4). Bleeding after EMR and side effects of the
study drugs were not found in any of the 51 patients. Drug
compliance was evaluated by counting remaining tablets.
Drug compliance was considered good if drug intake was
more than 75%. Compliance for therapy, i.e., the percent-
age of tablets taken (>75%), was 86.7% (26/30 patients)
and 92.6% (25/27 patients) in the rebamipide and famoti-
dine group, respectively, which was not significantly differ-
ent (P=0.673). 
DISCUSSION
The aim of this study was to evaluate the efficacy of reba-
mipide in ulcer healing after EMR by comparing it to famo-
tidine, which has already proven to be effective in the healing
of EMR-induced or peptic ulcers. PPI and H2RA are thera-
peutic agents for peptic ulcer diseases and PPI had been report-
ed to be more effective than H2RA in healing such ulcers
(14-18). Recently, an increase in the incidence of EMR thera-
py for gastric neoplasia has led to the increased interest in
the treatment of artificial ulcers after EMR. Recent studies
have demonstrated that PPI and H2RA are also effective in
EMR-induced ulcer healing. Some of those studies revealed
that PPI might be more potent than H2RA in the healing of
artificial ulcers created by EMR, especially larger ulcers after
ESD (4, 5, 8), whereas others have suggested that H2RAs
are comparable to PPIs in preventing bleeding and acceler-
ating ulcer healing with lower costs (19). Despite the fact that
both drugs are potent acid inhibitors, they are quite expensive.
In addition, PPIs are more expensive than H2RAs. Currently,
Korean national health insurance covers PPIs and H2RA in
cases of peptic ulcers, but not in those of EMR-induced ulcers.
PPI or H2RA treatment after EMR costs over twice as much
as peptic ulcer cases in Korea.
Although suppressors of acid secretion have been a main-
stay for the promotion of ulcer healing for three decades, a
better understanding of the mechanisms underlying mucos-
al defense has led to the development of novel anti-ulcer ther-
apies. Rebamipide has been studied in various clinical situa-
tions as an adjunct to anti-secretory therapy for the preven-
tion of gastric mucosal damage induced by NSAIDs, and the
prevention and treatment of peptic ulcer diseases. Although
clinical studies of rebamipide regarding peptic ulcers are still
limited, the efficacy of rebamipide in peptic ulcers caused by
H. pylori have been demonstrated. Several Japanese investi-
gations have demonstrated that rebamipide significantly pro-
moted gastric ulcer healing following one week of eradica-
tion therapy compared to placebo (1, 8). Furthermore, reba-
mipide is covered by health insurance in the case of EMR-
induced ulcers, and is less expensive than H2RA in Korea.
An economic benefit would be expected if rebamipide is used
in the management of EMR induced ulcers since it has a sim-
ilar efficacy to PPIs or H2RAs. Based on this background,
we hypothesized that the efficacy of rebamipide could be equal
to that of H2RA as a treatment option for EMR-induced gas-
tric ulcers. To prove this, we compared the efficacy and tol-
erability of rebamipide with those of famotidine. Our data
analysis of 51 patients indicated that the efficacy of rebamipi-
de was comparable to famotidine in terms of ulcer healing
and relief of ulcer-related symptoms. Moreover, drug side effect
rates were negligible and compliance to drug treatment was
excellent in both groups. In terms of costs and benefits, the
total costs required from the first day of EMR to day 28 were
19,320 won for famotidine and 15,750 won for rebamipide.
The cost-benefit ratio was significantly higher for rebamipi-
de; rebamipide could heal ulcers at only 81.5% of the cost
required by the famotidine treatment. 
These results that ulcer healing of patients in rebamipide
group was comparable to those in famotidine group, may be
partly explained by studies indicating that iatrogenic ulcers,
such as EMR-induced ulcers, heal faster than peptic ulcers.
The mechanisms of EMR-induced ulcer healing are not fully
understood, but some studies have found that they heal faster,
and recur less often (13). 
For one week after EMR, we randomly administered lanso-
prazole to all patients enrolled in the study regardless of their
treatment group. The incidence of bleeding after EMR had
been reported at 1.2-11.6% of patients in Japan (20). ESD is
a more complex procedure with a greater rate of complications.
One study performed in Korea reported that the rate of bleed-
ing after ESD reached 41.6% (21). Prevention of bleeding
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None, without epigastric pain; Mild, minimal epigastric pain; Moderate,
with epigastric pain without disturbing activities of daily living; Severe,
with epigastric pain with disturbing activities of daily living.
Rebamipide
group (n=26)
Pain degree
Famotidine
group (n=25)
P
value
None 17 (65.4%) 15 (60.0%) 0.151
Mild 7 (26.9%) 6 (24.0%)
Moderate 2 (7.7%) 4 (16.0%)
Severe - -
Table 4. The severity of epigastric pain during the treatment
period 
after EMR is crucial. Therefore, we were concerned about the
potential bleeding complications, which led to all patients
receiving lansoprazole during the first week after EMR to
reduce the risk of delayed bleeding. Therefore, this study did
not demonstrate what proportion one week of PPI contribut-
ed to the iatrogenic ulcer healing after EMR. The effect of
rebamipide on iatrogenic ulcers created by EMR would have
been better proved if we compared it with H2RA alone with-
out the use of PPI for one week. A study initiated in Korea
demonstrated that for EMR-induced ulcers, treatment with
omeprazole for one week is equivalent to the treatment with
omeprazole for four weeks, suggesting that shorter treatment
duration might be sufficient (13). However, in that study,
ESD cases were not included, and the mean size of ulcer cre-
ated by EMR was much smaller than those in the present
and other studies. To address these concerns, we additional-
ly performed a subgroup analysis in which only patients with
ESD were included. After ESD, a larger artificial ulceration
is created than those produced by snare polypectomy or EMR-
P. We found no overall differences between the rebamipide
and famotidine group in terms of ulcer stage or ulcer reduc-
tion ratio in the subgroup analysis. Moreover, since all ESD
procedures were performed by one specialized endoscopist,
ESD procedure was considered to be standardized. Therefore,
in our study, although PPI might have affect the ulcer heal-
ing in part, our aim to evaluate the efficacy of rebamipide
compared to H2RA could be accomplished by investigat-
ing relatively large iatrogenic ulcer created by ESD.
Factors that induce peptic ulcers include stress, chronic
alcohol consumption, intake of NSAIDs or aspirin, H. pylori
infection, and smoking (22). We excluded patients who should
continue to take NSAIDs, antiplatelet agents or glucocor-
ticoids. With regards to the proportion of current smokers,
there were no statistically significant differences between the
2 groups (2 in rebamipide vs. 4 in famotidine group) (Table
1). After 4 weeks after EMR, 5 patients (3 in rebamipide, 2
in famotidine group) showed that their ulcers stayed active
stage (A2) (Table 3). All these patients were not current smok-
ers and on good compliance to drugs. However, initial ulcer
sizes were greater with their mean size of 1,186 mm2, rang-
ing from 552 to 2009. No clinical factors were found to be
statistically significant in relation to the ulcer healing stage
after 4 weeks. This observation, although inadequate to be
concluded on the statistical evidences, suggests that ulcer
healing rate is mostly influenced by initial ulcer size, but not
by clinical or personal factors.
Although the present study is the first investigation that
demonstrates the efficacy of rebamipide in terms of ulcer heal-
ing after EMR, some limitations exist. The sample size used
was small and considerable numbers of patients (19.0% of
the initially included patients) were excluded from analysis.
Supplementary experimental investigations, such as measure-
ment of growth factor expression in patients with EMR-in-
duced ulcer, would provide a better understanding of the
mechanisms underlying artificial ulcer healing. Considering
the endemic H. pylori infection in Korea, the proportion of
positive CLO test in the present study was relatively low. Atro-
phy of background gastric mucosa combined to gastric neo-
plasm would contribute to a higher rate of false negative of
CLO test. However, we did not evaluate the histological exam-
ination of the surrounding gastric mucosa or serologic test
for H. pylori. Finally, hemoclipping is expected to influence
on ulcer healing and delayed bleeding either positively or neg-
atively. It was performed in 40-50% of patients in our study.
Although the proportion of patients who underwent hemo-
clipping after EMR was not significantly different in the 2
groups, it might have influenced the artificial ulcer healing. 
In conclusion, our data suggest that rebamipide is not infe-
rior to famotidine in terms of ulcer healing after EMR, and
may be an alternative for the treatment of EMR-induced ulcers. 
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